TD Asset Management Inc Buys 69,052 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE)

TD Asset Management Inc grew its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGEFree Report) by 217.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 100,846 shares of the company’s stock after purchasing an additional 69,052 shares during the quarter. TD Asset Management Inc owned about 0.20% of Apogee Therapeutics worth $2,818,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Amalgamated Bank bought a new position in Apogee Therapeutics during the third quarter worth $52,000. New York State Common Retirement Fund acquired a new position in Apogee Therapeutics in the third quarter valued at approximately $90,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $155,000. SG Americas Securities LLC increased its stake in shares of Apogee Therapeutics by 34.0% in the 4th quarter. SG Americas Securities LLC now owns 6,607 shares of the company’s stock valued at $185,000 after acquiring an additional 1,676 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new stake in shares of Apogee Therapeutics in the 3rd quarter valued at $337,000. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Price Performance

Shares of APGE stock opened at $41.69 on Friday. Apogee Therapeutics, Inc. has a one year low of $14.19 and a one year high of $72.29. The company has a market cap of $2.44 billion and a P/E ratio of -7.94. The firm has a 50-day moving average of $51.39 and a 200-day moving average of $41.63.

Apogee Therapeutics (NASDAQ:APGEGet Free Report) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). As a group, research analysts expect that Apogee Therapeutics, Inc. will post -2.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on APGE. Stifel Nicolaus increased their price target on Apogee Therapeutics from $46.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Guggenheim lifted their price target on shares of Apogee Therapeutics from $44.00 to $91.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Wedbush restated an “outperform” rating and set a $87.00 price objective on shares of Apogee Therapeutics in a report on Monday, May 13th. Bank of America assumed coverage on shares of Apogee Therapeutics in a report on Friday, May 10th. They set a “buy” rating and a $80.00 price objective for the company. Finally, Jefferies Financial Group upped their target price on shares of Apogee Therapeutics from $37.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Apogee Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $73.00.

Read Our Latest Report on APGE

Apogee Therapeutics Profile

(Free Report)

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

Further Reading

Want to see what other hedge funds are holding APGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Apogee Therapeutics, Inc. (NASDAQ:APGEFree Report).

Institutional Ownership by Quarter for Apogee Therapeutics (NASDAQ:APGE)

Receive News & Ratings for Apogee Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apogee Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.